

BARR PHARMACEUTICALS INC

Form 4

December 15, 2008

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SEAVER PETER

2. Issuer Name and Ticker or Trading  
Symbol  
BARR PHARMACEUTICALS INC  
[BRL]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
BARR PHARMACEUTICALS,  
INC., 400 CHESTNUT RIDGE  
ROAD

3. Date of Earliest Transaction  
(Month/Day/Year)  
12/11/2008

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_X\_\_\_\_ Officer (give title \_\_\_\_ Other (specify  
below) below)  
Insider

(Street)  
WOODCLIFF LAKE, NJ 07677

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_X\_\_\_\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Barr Pharmaceuticals, Inc.	12/11/2008		M	10,000	A \$ 48.84 10,000	D	
Barr Pharmaceuticals, Inc.	12/11/2008		M	10,000	A \$ 39.76 20,000	D	
Barr Pharmaceuticals, Inc.	12/11/2008		S	3,300	D \$ 65 16,700	D	

Edgar Filing: BARR PHARMACEUTICALS INC - Form 4

Barr Pharmaceuticals, Inc.	12/11/2008	S	3,000	D	\$ 65.01	13,700	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	400	D	\$ 65.005	13,300	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	900	D	\$ 65.007	12,400	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.008	12,100	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.015	11,900	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	3,700	D	\$ 65.02	8,200	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	100	D	\$ 65.025	8,100	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	700	D	\$ 65.03	7,400	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	500	D	\$ 65.035	6,900	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	1,200	D	\$ 65.04	5,700	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.047	5,400	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	900	D	\$ 65.05	4,500	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.06	4,300	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	600	D	\$ 65.07	3,700	D
Barr Pharmaceuticals,	12/11/2008	S	700	D	\$ 65.08	3,000	D

Edgar Filing: BARR PHARMACEUTICALS INC - Form 4

Inc.

Barr Pharmaceuticals, Inc.	12/11/2008	S	600	D	\$ 65.11	2,400	D
----------------------------	------------	---	-----	---	----------	-------	---

Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.12	2,200	D
----------------------------	------------	---	-----	---	----------	-------	---

Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.15	2,000	D
----------------------------	------------	---	-----	---	----------	-------	---

Barr Pharmaceuticals, Inc.	12/11/2008	S	400	D	\$ 65.17	1,600	D
----------------------------	------------	---	-----	---	----------	-------	---

Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.18	1,300	D
----------------------------	------------	---	-----	---	----------	-------	---

Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.19	1,000	D
----------------------------	------------	---	-----	---	----------	-------	---

Barr Pharmaceuticals, Inc.	12/11/2008	S	1,000	D	\$ 65.22	0	D
----------------------------	------------	---	-------	---	----------	---	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title
Director Stock Plan	\$ 48.84	12/11/2008		M	10,000	05/17/2007 10/09/2016	Barr Pharmaceuticals, Inc.

Director

Stock \$ 39.76 12/11/2008  
Plan

M

10,000 11/21/2008 05/15/2018 Barr  
Pharmaceuticals, Inc.

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SEAVER PETER BARR PHARMACEUTICALS, INC. 400 CHESTNUT RIDGE ROAD WOODCLIFF LAKE, NJ 07677			Insider	

## Signatures

S/S William T. McKee as Attorney-in-Fact for Peter  
Seaver

12/15/2008

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

### Remarks:

This is a multi-filing. This is Form 2 of 2 for Peter Seaver's activity on 12/11/2008

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.